| 發表者 | 討論主題：NEvfWGXuwlnNPcisabF | ||
| Robert | 9/10/2014 11:29:48 PM [瞼羸瞼?]•[繡礙簞T繚~]•[竄?穠F聶瞻瞼竄] | 
|
|
| What company are you calling from? http://www.manhasset-specialty.com/sterling-silver-3d-slot/ sterling silver 3d slot CANbridge has already signed a deal with Texas-based Azaya Therapeutics to develop ATI-1123 for non-small cell lung cancer and potentially other solid tumours. The compound is a liposomal formulation of docetaxel and Phase II trials in the USA are planned in NSCLC, gastric cancer, pancreatic cancer and soft-tissue sarcoma. | |||